MXPA05011750A - Celulas madre hematopoyeticas y metodos de tratamiento de enfermedades oculares neovasculares con las mismas. - Google Patents

Celulas madre hematopoyeticas y metodos de tratamiento de enfermedades oculares neovasculares con las mismas.

Info

Publication number
MXPA05011750A
MXPA05011750A MXPA05011750A MXPA05011750A MXPA05011750A MX PA05011750 A MXPA05011750 A MX PA05011750A MX PA05011750 A MXPA05011750 A MX PA05011750A MX PA05011750 A MXPA05011750 A MX PA05011750A MX PA05011750 A MXPA05011750 A MX PA05011750A
Authority
MX
Mexico
Prior art keywords
cells
lin
hsc
population
trprs
Prior art date
Application number
MXPA05011750A
Other languages
English (en)
Spanish (es)
Inventor
Atsushi Otani
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/628,783 external-priority patent/US7153501B2/en
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of MXPA05011750A publication Critical patent/MXPA05011750A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MXPA05011750A 2003-05-02 2004-04-28 Celulas madre hematopoyeticas y metodos de tratamiento de enfermedades oculares neovasculares con las mismas. MXPA05011750A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46705103P 2003-05-02 2003-05-02
US10/628,783 US7153501B2 (en) 2002-07-25 2003-07-25 Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
PCT/US2004/012989 WO2004098499A2 (en) 2002-07-25 2004-04-28 Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith

Publications (1)

Publication Number Publication Date
MXPA05011750A true MXPA05011750A (es) 2006-06-06

Family

ID=36908146

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA05011750A MXPA05011750A (es) 2003-05-02 2004-04-28 Celulas madre hematopoyeticas y metodos de tratamiento de enfermedades oculares neovasculares con las mismas.
MXPA05011752A MXPA05011752A (es) 2003-05-02 2004-04-28 Celulas madre hematopoyeticas y metodos de tratamiento de enfermedades oculares neovasculares con las mismas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MXPA05011752A MXPA05011752A (es) 2003-05-02 2004-04-28 Celulas madre hematopoyeticas y metodos de tratamiento de enfermedades oculares neovasculares con las mismas.

Country Status (10)

Country Link
EP (2) EP1624758A4 (enExample)
JP (2) JP4714682B2 (enExample)
KR (3) KR101169261B1 (enExample)
CN (2) CN1831119B (enExample)
AU (2) AU2004237749B2 (enExample)
BR (1) BRPI0409861A (enExample)
CA (2) CA2524063C (enExample)
MX (2) MXPA05011750A (enExample)
RU (2) RU2345780C2 (enExample)
ZA (2) ZA200509752B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2554662A1 (en) * 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
CN110777124A (zh) 2011-10-27 2020-02-11 威尔斯达眼科制剂公司 编码视杆细胞来源的视锥细胞活力因子的载体
RU2495650C1 (ru) * 2012-02-29 2013-10-20 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Трехкомпонентный комплекс для клеточной терапии в офтальмологии
RU2485922C1 (ru) * 2012-03-28 2013-06-27 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Способ лечения "сухой" формы возрастной макулярной дегенерации
CN107043699B (zh) * 2017-04-25 2023-04-07 徐子雁 一种低能量激光诱导间充质干细胞血管化的试剂盒

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002033043A2 (en) * 2000-10-18 2002-04-25 Coriell Institute For Medical Research Method and marker for the isolation of human multipotent hematopoietic stem cells
CN1307300C (zh) * 2002-07-25 2007-03-28 斯克里普斯研究学院 造血干细胞和治疗新生血管性眼部疾病的方法

Also Published As

Publication number Publication date
EP1624758A2 (en) 2006-02-15
AU2005239702A1 (en) 2005-12-22
KR20060056420A (ko) 2006-05-24
JP2006166918A (ja) 2006-06-29
CN1816281A (zh) 2006-08-09
CA2524063A1 (en) 2004-11-18
CN100439493C (zh) 2008-12-03
EP1754783A1 (en) 2007-02-21
RU2389497C2 (ru) 2010-05-20
AU2005239702B2 (en) 2010-03-04
JP4714580B2 (ja) 2011-06-29
JP4714682B2 (ja) 2011-06-29
CA2524063C (en) 2015-02-17
CA2526670C (en) 2011-06-14
ZA200509756B (en) 2006-10-25
BRPI0409861A (pt) 2006-05-16
KR20120034251A (ko) 2012-04-10
ZA200509752B (en) 2006-11-29
KR101169261B1 (ko) 2012-08-03
MXPA05011752A (es) 2006-06-06
RU2005137569A (ru) 2006-06-10
CN1831119A (zh) 2006-09-13
CA2526670A1 (en) 2004-11-18
JP2006525806A (ja) 2006-11-16
EP1624758A4 (en) 2007-03-07
AU2004237749A1 (en) 2004-11-18
RU2006103574A (ru) 2007-08-20
KR101224375B1 (ko) 2013-01-21
RU2345780C2 (ru) 2009-02-10
KR20060008968A (ko) 2006-01-27
AU2004237749B2 (en) 2011-09-15
CN1831119B (zh) 2010-05-26

Similar Documents

Publication Publication Date Title
CA2493122C (en) Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
CN101594781A (zh) 分离的髓样细胞群及其治疗方法
KR100869914B1 (ko) 혈관 형성 조절에 유용한 트립토파닐-ｔＲＮＡ 신세타제기원 폴리펩타이드
US20020182666A1 (en) Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
IL195854A (en) Aminoacyl polypeptides - trna human synthesis used to regulate angiogenesis
PT1935976E (pt) Células do tipo mielóide transfectadas para o tratamento de retinopatia da prematuridade e doenças relacionadas
CA2526670C (en) Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
US6387664B1 (en) Sparc fusion protein and method for producing the same
KR101309500B1 (ko) 분리된 계통 음성 조혈 줄기세포 및 이를 사용한 치료 방법
CN104328136B (zh) 鸡新城疫病毒毒株rClone30‑fliC的制备及其在鸡新城疫病防治中的应用
CN115247173A (zh) 构建tmprss6基因突变的缺铁性贫血猪核移植供体细胞的基因编辑系统及其应用
CN115232813B (zh) 用于构建vWF基因突变的血管性血友病模型猪核移植供体细胞的基因编辑系统及其应用
JP3012930B1 (ja) Ｓｐａｒｃ融合タンパク質含有医薬組成物
KR100902634B1 (ko) 재조합 ｈｍｇｂ1 펩티드를 포함하는 핵산 전달 복합체
CN116135880A (zh) 一株羊驼源纳米抗体s140及其应用
CN115232834A (zh) 用于构建oca-1a型白化病模型猪核移植供体细胞的基因编辑系统及其应用
CN115232796A (zh) 构建mkrn3基因突变的中枢性性早熟模型猪核移植供体细胞的基因编辑系统及其应用

Legal Events

Date Code Title Description
FG Grant or registration